Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th. American Psychiatric Publishing; 2013.
   Google Scholar
• Jiang R, Lee I, Lee TA, Pickard AS. The societal cost of heroin use disorder in the United States. PLoS One. 2017;12(5). doi:10.1371/journal.pone.0177323
   Web of Science ®Google Scholar
• Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012. doi:10.1016/S2215-0366(18)30337-7
   PubMed Web of Science ®Google Scholar
• Eibl JK, Morin K, Leinonen E, Marsh DC. The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight. Canadian J Psychiatry. 2017;62(7):444–450. doi:10.1177/0706743717711167
   PubMed Web of Science ®Google Scholar
• Illicit Drug Toxicity Deaths in BC: January 1, 2012 – June 30, 2022; 2022.
   Google Scholar
• de Jong CAJ, Roozen HG, van Rossum LGM, Krabbe PFM, Kerkhof AJFM. High abstinence rates in heroin addicts by a new comprehensive treatment approach. Am J Addictions. 2007;16(2):124–130. doi:10.1080/10550490601184472
   PubMed Web of Science ®Google Scholar
• Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017;63(3):200.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Sys Rev. 2014;2014(2):548. doi:10.1002/14651858.CD002207.pub4
   Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Sys Rev. 2009;1(3):1222. doi:10.1002/14651858.CD002209.pub2
   Web of Science ®Google Scholar
• Beck T, Haasen C, Verthein U, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction. 2014;109(4):617–626. doi:10.1111/add.12440
   PubMed Web of Science ®Google Scholar
• Piske M, Zhou H, Min JE, et al. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction. 2020;115(8):1482–1493. doi:10.1111/add.14947
   PubMed Web of Science ®Google Scholar
• Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. THE BMJ. 2020:368. doi:10.1136/bmj.m772
   Web of Science ®Google Scholar
• Wei X, Wang L, Wang X, Li J, Li H, Jia W. A study of 6-year retention in methadone maintenance treatment among opioid-dependent patients in xi’an. J Addict Med. 2013;7(5):342–348. doi:10.1097/ADM.0b013e31829da05b
   PubMed Web of Science ®Google Scholar
• Perreault M, Julien D, White ND, Rabouin D, Lauzon P, Milton D. Psychological predictors of retention in a low-threshold methadone maintenance treatment for opioid addicts: a 1-year follow-up study. Subst Use Misuse. 2015;50(1):24–31. doi:10.3109/10826084.2014.957769
   PubMed Web of Science ®Google Scholar
• Schottenfeld RS, O’Malley SS. Meeting the growing need for heroin addiction treatment. JAMA Psychiatry. 2016;73(5):437. doi:10.1001/jamapsychiatry.2016.0139
   PubMed Web of Science ®Google Scholar
• Taqi MM, Faisal M, Zaman H. OPRM1 A118G polymorphisms and its role in opioid addiction: implication on severity and treatment approaches. Pharmgenomics Pers Med. 2019;12:361–368. doi:10.2147/PGPM.S198654
   PubMed Web of Science ®Google Scholar
• Li Y, Kantelip JP, Gerritsen-Van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12(2):109–124. doi:10.1007/BF03256276
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Eng J Med. 2009;361(8):777–786. doi:10.1056/nejmoa0810635
   PubMed Web of Science ®Google Scholar
• Strang J, Metrebian N, Lintzeris N, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375(9729):1885–1895. doi:10.1016/S0140-6736(10)60349-2
   PubMed Web of Science ®Google Scholar
• Demaret I, Quertemont E, Litran G, et al. Efficacy of heroin-assisted treatment in Belgium: a randomised controlled trial. Eur Addict Res. 2015;21(4):179–187. doi:10.1159/000369337
   PubMed Web of Science ®Google Scholar
• Bansback N, Guh D, Oviedo-Joekes E, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264–1273. doi:10.1111/add.14171
   PubMed Web of Science ®Google Scholar
• Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012;184(6):E317–E328. doi:10.1503/cmaj.110669
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Guh D, Brissette S, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence. JAMA Psychiatry. 2016;73(5):447. doi:10.1001/jamapsychiatry.2016.0109
   PubMed Web of Science ®Google Scholar
• Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1). doi:10.1186/s13011-020-0253-y
   PubMed Web of Science ®Google Scholar
• Palis H, Marchand K, Beaumont S, et al. Physician communication in injectable opioid agonist treatment: collecting patient ratings with the communication assessment tool. J Addict Med. 2020;14(6):480–488. doi:10.1097/ADM.0000000000000631
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;16(1). doi:10.1186/s13011-021-00358-x
   Web of Science ®Google Scholar
• Eydt E, Glegg S, Sutherland C, et al. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. CMAJ Open. 2021;9(1):E115–E124. doi:10.9778/cmajo.20200021
   PubMedGoogle Scholar
• Trujols J, Portella MJ, Iraurgi I, Campins MJ, Siñol N, Cobos JPDL. Patient-reported outcome measures: are they patient-generated, patient-centred or patient-valued? J Mental Health. 2013;22(6):555–562. doi:10.3109/09638237.2012.734653
   PubMed Web of Science ®Google Scholar
• Friedrichs A, Spies M, Härter M, Buchholz A. Patient preferences and shared decision making in the treatment of substance use disorders: a systematic review of the literature. PLoS One. 2016;11(1):e0145817. doi:10.1371/journal.pone.0145817
   PubMed Web of Science ®Google Scholar
• Roux P, Rojas Castro D, Ndiaye K, et al. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. Subst Abuse Treat Prev Policy. 2017;12(1). doi:10.1186/s13011-017-0131-4
   PubMed Web of Science ®Google Scholar
• Ryan M. Using conjoint analysis to elicit preferences for health care. Br Med J. 2000;320(7248):1530–1533. doi:10.1136/bmj.320.7248.1530
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - A checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Mühlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making? Appl Health Econ Health Policy. 2013;11(3):163–180. doi:10.1007/s40258-013-0023-3
   PubMedGoogle Scholar
• Wilder CM, Elbogen EB, Moser LL, Swanson JW, Swartz MS. Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. Psychiatric Services. 2010;61(4):380–385. doi:10.1176/ps.2010.61.4.380
   PubMed Web of Science ®Google Scholar
• Gaulen Z, Brenna IH, Fadnes LT, et al. The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. Eur Addict Res. 2022;28(1):56–67. doi:10.1159/000518436
   PubMed Web of Science ®Google Scholar
• Cheung KL, Wijnen BFM, Hollin IL, et al. Using Best–Worst Scaling to Investigate Preferences in Health Care. Pharmacoeconomics. 2016;34(12):1195–1209. doi:10.1007/s40273-016-0429-5
   PubMed Web of Science ®Google Scholar
• Flynn TN, Louviere JJ, Peters TJ, Coast J. Best-worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171–189. doi:10.1016/j.jhealeco.2006.04.002
   PubMed Web of Science ®Google Scholar
• Mühlbacher AC, Kaczynski A, Zweifel P, Johnson FR. Experimental measurement of preferences in health and healthcare using best-worst scaling: an overview. Health Econ Rev. 2016;6(1):1–4. doi:10.1186/s13561-015-0079-x
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Emsley R, Ashcroft D, et al. Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. Lung Cancer. 2012;77(1):199–204. doi:10.1016/j.lungcan.2012.02.001
   PubMed Web of Science ®Google Scholar
• Wittenberg E, Bharel M, Saada A, Santiago E, Bridges JFP, Weinreb L. Measuring the preferences of homeless women for cervical cancer screening interventions: development of a best–worst scaling survey. Patient. 2015;8(5):455–467. doi:10.1007/s40271-014-0110-z
   PubMedGoogle Scholar
• Mohapatra S, Cheung KL, Hiligsmann M, Anokye N. Most important factors for deciding rehabilitation provision for severe stroke survivors post hospital discharge: a study protocol for a best–worst scaling experiment. Methods Protoc. 2021;4(2):27. doi:10.3390/mps4020027
   PubMedGoogle Scholar
• Castillo WC, Ross M, Tariq S, Dos Reis S. Best-worst scaling to prioritize outcomes meaningful to caregivers of youth with mental health multimorbidities: a pilot study. J Dev Behav Pediatrics. 2018;39(2):101. doi:10.1097/DBP.0000000000000525
   PubMed Web of Science ®Google Scholar
• Wittenberg E, Bharel M, Bridges JFP, Ward Z, Weinreb L. Using best-worst scaling to understand patient priorities: a case example of Papanicolaou tests for homeless women. Ann Fam Med. 2016;14(4):359–364. doi:10.1370/afm.1937
   PubMed Web of Science ®Google Scholar
• Howard K, Anderson K, Cunningham J, et al. What Matters 2 Adults: a study protocol to develop a new preference-based wellbeing measure with Aboriginal and Torres Strait Islander adults (WM2Adults). BMC Public Health. 2020;20(1). doi:10.1186/s12889-020-09821-z
   Web of Science ®Google Scholar
• Ratcliffe J, Couzner L, Flynn T, et al. Valuing child health utility 9D health states with a young adolescent sample: a feasibility study to compare best-worst scaling discrete-choice experiment, standard gamble and time trade-off methods. Appl Health Econ Health Policy. 2011;9(1):15–27. doi:10.2165/11536960-000000000-00000
   PubMedGoogle Scholar
• Palis H, Marchand K, Guh D, et al. Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder. Subst Abuse Treat Prev Policy. 2017;12(1). doi:10.1186/s13011-017-0110-9
   PubMed Web of Science ®Google Scholar
• Dobischok S, Metcalfe R, Matzinger E, et al. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a Person-Centered Scale (Best-Worst Scaling). International Journal of Drug Policy. 2022. In press
   PubMed Web of Science ®Google Scholar
• Höhne JK, Schlosser S, Krebs D. Investigating cognitive effort and response quality of question formats in web surveys using paradata. Field Methods. 2017;29(4):365–382. doi:10.1177/1525822X17710640
   Web of Science ®Google Scholar